Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A novel TRMT5 mutation causes a complex inherited neuropathy syndrome: The role of nerve pathology in defining a demyelinating neuropathy

  • Argente-Escrig, Herminia
  • Vílchez, Juan Jesús
  • Frasquet, Marina
  • Muelas, Nuria
  • Azorín, Inmaculada
  • Vílchez, Roger
  • Millet-Sancho, Elvira
  • Pitarch, Inmaculada
  • Tomás-Vila, Miguel
  • Vazquez-Costa, Juan F.
  • Mas-Estellés, Fernando
  • Marco-Marín, Clara
  • Espinós, Carmen
  • Serrano-Lorenzo, Pablo
  • Martín, Miguel A.
  • Lupo, Vincenzo
  • Sevilla, Teresa
14 páginas, 4 figuras, 3 tablas, Aims: We aim to present data obtained from three patients belonging to three unrelated families with an infantile onset demyelinating neuropathy associated to somatic and neurodevelopmental delay and to describe the underlying genetic changes. Methods: We performed whole-exome sequencing on genomic DNA from the patients and their parents and reviewed the clinical, muscle and nerve data, the serial neurophysiological studies, brain and muscle MRIs, as well as the respiratory chain complex activity in the muscle of the three index patients. Computer modelling was used to characterise the new missense variant detected. Results: All three patients had a short stature, delayed motor milestone acquisition, intellectual disability and cerebellar abnormalities associated with a severe demyelinating neuropathy, with distinct morphological features. Despite the proliferation of giant mitochondria, the mitochondrial respiratory chain complex activity in skeletal muscle was normal, except in one patient in whom there was a mild decrease in complex I enzyme activity. All three patients carried the same two compound heterozygous variants of the TRMT5 (tRNA Methyltransferase 5) gene, one known pathogenic frameshift mutation [c.312_315del (p.Ile105Serfs*4)] and a second rare missense change [c.665 T > C (p.Ile222Thr)]. TRMT5 is a nuclear-encoded protein involved in the post-transcriptional maturation of mitochondrial tRNA. Computer modelling of the human TRMT5 protein structure suggests that the rare p.Ile222Thr mutation could affect the stability of tRNA binding. Conclusions: Our study expands the phenotype of mitochondrial disorders caused by TRTM5 mutations and defines a new form of recessive demyelinating peripheral neuropathy., Fundación Isabel Gemio; Generalitat Valenciana, Grant/Award Number:PROMETEO/2018/13; Fondo Europeo deDesarrollo Regional (FEDER); Instituto deSalud Carlos III, Grant/Award Numbers:PI19/01178, PI18/01374, PI16/00403, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Characterizing SOD1 mutations in Spain. The impact of genotype, age, and sex in the natural history of the disease

  • Vázquez-Costa, Juan F.
  • Borrego-Hernández, Daniel
  • Paradas, Carmen
  • Gómez-Caravaca, María Teresa
  • Rojas-García, Ricardo
  • Varona, Luis
  • Povedano, Mónica
  • García-Sobrino, Tania
  • Jericó Pascual, Ivonne
  • Gutiérrez, Antonio
  • Riancho, Javier
  • Turón-Sans, Janina
  • Assialioui, Abdelilah
  • Pérez-Tur, Jordi
  • Sevilla, Teresa
  • Esteban Pérez, Jesús
  • García-Redondo, Alberto
11 páginas, 3 figuras, 2 tablas, Introduction: The aim of this study is to describe the frequency and distribution of SOD1 mutations in Spain, and to explore those factors contributing to their phenotype and prognosis. Methods: Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. Results: In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all 5 exons of SOD1, including 7 novel mutations. 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. Its frequency varied considerably between regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp(Estimate) = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (HR = 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated to faster disease progression (exp(Estimate) = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs 301 months). Conclusions: These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments., This study has received funding from: Instituto de Salud Carlos III (21/00737 PI J.F.V.C., 19/01178 PI T.S., PI 19/01543 to R.R.), cofunded by European Regional Development Fund (‘A way to make Europe’); STOPELA (2017/0653); I + D biomedicina 2017 from Comunidad de Madrid ‘ELA-Madrid’ (B2017/BMD-3813 to A.G.-R.); estrategias frente a Enfermedades Neurodegenerativas Ministerio de Sanidad – Comunidad de Madrid B.O.C.M. Num. 142 - Lunes 17 de junio de 2019 - Pág. 10 ‘Estudio genético de la población con ELA de la Comunidad de Madrid’ to A.G.-R. The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the ISCIII. J.F.V.C., T.S., C.P., M.P., R.R.-G., J.T.S. and R.J.M. are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Charcot-Marie-Tooth disease due to MORC2 mutations in Spain

  • Sivera, Rafael|||0000-0003-2810-1180
  • Lupo, Vincenzo|||0000-0002-3774-9854
  • Frasquet, Marina
  • Argente-Escrig, Herminia
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Querol, Luis|||0000-0002-4289-8264
  • García-Romero, María del Mar
  • Ignacio Pascual, Samuel
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Paradas, Carmen|||0000-0002-6917-2236
  • Vázquez-Costa, Juan F.|||0000-0002-3043-7938
  • Muelas, Nuria|||0000-0002-2349-7481
  • Millet, Elvira
  • Vílchez, Juan J.|||0000-0002-0532-2872
  • Espinós, Carmen|||0000-0003-4435-1809
  • Sevilla, T.
IIB., Background and purpose: MORC2 mutations have been described as a rare cause of axonal Charcot-Marie-Tooth disease (CMT2Z). The aim of this work was to determine the frequency and distribution of these mutations throughout Spain, to provide a comprehensive phenotypical description and, if possible, to establish a genotype-phenotype correlation. Methods: Retrospectively, data on patients diagnosed with CMT2Z in Spain were collected and clinical, electrophysiological and muscle imaging information were analysed. Results: Fifteen patients with CMT2Z were identified throughout Spain, seven of them belonging to a single kindred, whilst the rest were sporadic. The most common mutation was p.R252W, and four new mutations were identified. Eleven patients were categorized as having a scapuloperoneal phenotype, with asymmetric muscle weakness, early proximal upper limb involvement and frequent spontaneous muscular activity with distal sensory impairment and pes cavus, whilst two presented with a more classic length dependent sensory motor phenotype. This distinction was corroborated by the distribution of muscle fatty infiltration in muscle imaging. Two other patients were classified as having a neurodevelopmental phenotype consisting in congenital or early onset, delay in motor milestones, and global developmental delay in one of them. Nerve conduction studies revealed an unequivocally axonal neuropathy with frequent spontaneous activity, and serum creatine kinase levels were increased in 50% of the patients. Conclusions: MORC2 mutations are a rare cause of CMT in Spain, but in-depth phenotyping reveals a recognizable phenotypic spectrum that will be clinically relevant for future identification of this disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dystrophinopathy Phenotypes and Modifying Factors in Exon 45-55 Deletion

  • Poyatos-García, Javier|||0000-0003-3117-4743
  • Martí, Pilar|||0000-0002-1022-9314
  • Liquori, Alessandro|||0000-0002-4842-5986
  • Muelas, Nuria|||0000-0002-2349-7481
  • Pitarch, Inmaculada|||0000-0002-3864-7374
  • Martinez-Dolz, Luis|||0000-0001-5145-8191
  • Rodríguez, Benjamin
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Damiá, Maria|||0000-0003-2933-8438
  • Aller, Elena|||0000-0001-7973-5250
  • Selva-Gimenez, Marta|||0000-0003-4084-7356
  • Vilchez, Roger
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Bárcena LLona, Jose Eulalio|||0000-0002-7156-5960
  • Jauregui, Amaia
  • Gamez, Josep|||0000-0003-3127-7486
  • Aladrén, Jesus Angel
  • Fernández, Ariadna
  • Montolio, Marisol|||0000-0001-5494-5737
  • Azorin, Inmaculada
  • Hervas, David|||0000-0003-0635-4961
  • Casasús, Ana
  • Nieto, Marisa
  • Gallano, Pia|||0000-0001-8104-2197
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Vílchez, Juan J.|||0000-0002-0532-2872
Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients, but the associated clinical variability and complications require clarification. We aimed to understand the phenotypes and potential modifying factors of this dystrophinopathy subset. This cross-sectional, multicenter cohort study applied clinical and functional evaluation. Next generation sequencing was employed to identify intronic breakpoints and their impact on the Dp140 promotor, intronic long noncoding RNA, and regulatory splicing sequences. DMD modifiers (SPP1, LTBP4, ACTN3) and concomitant mutations were also assessed. Haplotypes were built using DMD single nucleotide polymorphisms. Dystrophin expression was evaluated via immunostaining, Western blotting, reverse transcription polymerase chain reaction (PCR), and droplet digital PCR in 9 muscle biopsies. The series comprised 57 subjects (23 index) expressing Becker phenotype (28%), isolated cardiopathy (19%), and asymptomatic features (53%). Cognitive impairment occurred in 90% of children. Patients were classified according to 10 distinct index-case breakpoints; 4 of them were recurrent due to founder events. A specific breakpoint (D5) was associated with severity, but no significant effect was appreciated due to the changes in intronic sequences. All biopsies showed dystrophin expression of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterizing SOD1 mutations in Spain, The impact of genotype, age and sex in the natural history of the disease

  • Vázquez-Costa, Juan F.|||0000-0002-3043-7938
  • Borrego-Hernández, Daniel
  • Paradas, Carmen|||0000-0002-6917-2236
  • Gómez-Caravaca, María Teresa
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Varona, Luis|||0000-0001-6256-5478
  • Povedano, Mónica
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Riancho, Javier|||0000-0001-7929-1055
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Assialioui, Abdelilah|||0000-0002-1381-9600
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Esteban Pérez, Jordi
  • García-Redondo, Alberto
  • Andrés López, Alberto
  • Calabria, M. Dolores
  • Díaz-Marín, Carmen
  • Fages Caravaca, Eva
  • Galán Dávila, Lucía
  • García Martínez, Alberto
  • Gimenez-Muñoz, Álvaro
  • Guerrero Sola, Antonio
  • Mascías Cadavid, Javier
  • Mora Pardina, Jesús S.
  • Muñoz-Blanco, José Luis
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • Morgado, Yolanda
  • Pardo, Julio|||0000-0001-8807-1310
  • Valladares, Amador
  • Vilar-Ventura, Rosa María
The aim of this study was to describe the frequency and distribution of SOD1 mutations in Spain, and to explore factors contributing to their phenotype and prognosis. Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic SOD1 variants. Multivariable models were used to explore prognostic modifiers. In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of SOD1, including seven novel mutations. A total of 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were estimated to carry SOD1 mutations. The frequency of this mutation varied considerably among regions, due to founder events. The most frequent mutation was p.Gly38Arg (n = 58), followed by p.Glu22Gly (n = 11), p.Asn140His (n = 10), and the novel p.Leu120Val (n = 10). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression (exp[Estimate] = 1.03 [0.01, 0.05], p = 0.001) and poorer survival (hazard ratio 1.05 [1.01, 1.08], p = 0.007), regardless of the underlying mutation. Female sex was independently associated with faster disease progression (exp[Estimate] = 2.1 [1.23, 3.65], p = 0.012) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs. 301 months). These data may help to evaluate the efficacy of SOD1 targeted treatments, and to expand the number of patients that might benefit from these treatments.